Photo Credit: stocky01
The following is a summary of “Relationship between serum levels of LOX-1, hs-cTnT, NGAL, and renal function, and their diagnostic value in patients with chronic kidney disease: a retrospective study,” published in the November 2024 issue of Nephrology by Chai et al.
Researchers conducted a retrospective study to explore the relationship between serum levels of LOX-1, hs-cTnT, and NGAL, and renal function in patients with chronic kidney disease (CKD), evaluating their diagnostic value for early detection and monitoring of disease progression.
They conducted a retrospective study on 108 patients with CKD admitted between January and December 2023, dividing them into mild renal insufficiency (51 cases) and severe renal insufficiency (57 cases) groups. They compared serum levels of LOX-1, hs-cTnT, and NGAL between the groups, using Pearson correlation analysis to explore their relationship with renal function. ROC analysis was performed to evaluate the diagnostic value of these markers for CKD.
The results showed that serum levels of LOX-1, hs-cTnT, and NGAL were significantly lower in the mild renal insufficiency group compared to the severe group (P < 0.05). Correlation analysis revealed positive correlations between these markers and renal function deterioration (P < 0.001). ROC analysis showed AUC values of 0.859 for LOX-1, 0.882 for hs-cTnT, and 0.841 for NGAL, indicating their significant predictive value for CKD diagnosis.
They found that serum levels of LOX-1, hs-cTnT, and NGAL were closely associated with the severity of renal impairment in patients with CKD.
Source: bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03875-6
